# Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015

> **NCT01125917** · PHASE3 · TERMINATED · sponsor: **Purdue Pharma LP** · enrollment: 354 (actual)

## Conditions studied

- Back Pain Lower Back Chronic

## Interventions

- **DRUG:** Buprenorphine transdermal patch
- **DRUG:** Buprenorphine transdermal patch
- **DRUG:** Buprenorphine transdermal patch

## Key facts

- **NCT ID:** NCT01125917
- **Lead sponsor:** Purdue Pharma LP
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-06
- **Primary completion:** 2005-09
- **Final completion:** 2008-01
- **Target enrollment:** 354 (ACTUAL)
- **Why stopped:** Terminated early due to administrative reasons.
- **Last updated:** 2012-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01125917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01125917, "Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01125917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*